Akorn +9.5% as Fresenius confirms M&A discussions

|By:, SA News Editor

Akorn (NASDAQ:AKRX) +9.5% AH after Fresenius (NYSE:FMS) confirms discussions concerning a potential acquisition of the company.

Shares finished 18% higher in regular trade following earlier reports of potential M&A interest from FMS.

AKRX could complement FMS's Kabi medicines division, which specializes in intravenous drugs, and accounts for ~20% of the company’s revenue.